Abstract:Despite being mutated in 92% of TP53 mutant cancers, how mutations on p53 isoforms affect their activities remain largely unknown. Therefore, exploring the effect of mutations on p53 isoforms activities is a critical, albeit unexplored area in the p53 field. In this article, we report for the first time a mutant Δ133p53α-specific pathway which increases IL4I1 and IDO1 expression and activates AHR, a tumor-promoting mechanism. Accordingly, while WT Δ133p53α reduces apoptosis to promote DNA repair, mutant R273H also reduces apoptosis but fails to maintain genomic stability, increasing the risks of accumulation of mutations and tumor's deriving towards a more aggressive phenotype. Furthermore, using 2D and 3D spheroids culture, we show that WT Δ133p53α reduces cell proliferation, EMT, and invasion, while the mutant Δ133p53α R273H enhances all three processes, confirming its oncogenic potential and strongly suggesting a similar in vivo activity. Importantly, the effects on cell growth and invasion are independent of mutant full-length p53α, indicating that these activities are actively carried by mutant Δ133p53α R273H. Furthermore, both WT and mutant Δ133p53α reduce cellular senescence in a senescence inducer-dependent manner (temozolomide or radiation) because they regulate different senescence-associated target genes. Hence, WT Δ133p53α rescues temozolomide-induced but not radiation-induced senescence, while mutant Δ133p53α R273H rescues radiation-induced but not temozolomide-induced senescence. Lastly, we determined that IL4I1, IDO1, and AHR are significantly higher in GBMs compared to low-grade gliomas. Importantly, high expression of all three genes in LGG and IL4I1 in GBM is significantly associated with poorer patients' survival, confirming the clinical relevance of this pathway in glioblastomas. These data show that, compared to WT Δ133p53α, R273H mutation reorientates its activities toward carcinogenesis and activates the oncogenic IL4I1/IDO1/AHR pathway, a potential prognostic marker and therapeutic target in GBM by combining drugs specifically modulating Δ133p53α expression and IDO1/Il4I1/AHR inhibitors.

Effects of Wild-Type P53 Expression on the Quantity and Activity of Topoisomerase Ii Alpha and Beta in Various Human Cancer Cell Lines

P53 Regulates the Minimal Promoter of the Human Topoisomerase Ii Alpha Gene

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition

[Effect of Wt P53 Gene Transfection on Sensitivity of Hyperthermia in C6 Glioma Cells].

Effect of transfection of wild-type p53 gene on sensitivity of T cell lymphoma to chemotherapy

Inactivation Of P53 Increases The Cytotoxicity Of Camptothecin In Human Colon Hct116 And Breast Mcf-7 Cancer Cells

P53 Gene Mutations Are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents.

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Expression of mutant p53 affects cancer cell sensitivity to topotecan

Modulation of Cisplatinum Cytotoxicity by P53: Effect of P53-Mediated Apoptosis and DNA Repair

Wild Type P53 Increased Chemosensitivity Of Drug-Resistant Human Hepatocellular Carcinoma Be17402/5-Fu Cells

Cell-Type, Dose, and Mutation-Type Specificity Dictate Mutant P53 Functions in Vivo

[The Relationship of P53 and the Cytotoxicity Mediated by TM-TNF-alpha and S-TNF-alpha].

Molecular Mechanism of Wild-type P53 Gene Enhancing Chemosensitivity of Human Colorectal Cancer Cells to 5-FU

Effect of P53 Gene Transfection on Human Hepatocarcinoma Cells' Sensitivity to Irradiation.

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site

Inhibitory Effect of Bcl-2 on P53-Mediated Transactivation Following Genotoxic Stress

Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence

Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment

Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type P53 but Not Mutant P53 to Topotecan Treatment